|
Dr. Cherrington is the President of San Diego based Phenomix Corporation with strategic and operational responsibility for research and development at the discovery, pre-clinical and clinical stages. In addition to guiding Phenomix� assets through clinical trials Dr. Cherrington plays a lead role in corporate activities including financing, corporate and business development. Prior to joining Phenomix in 2003, Dr. Cherrington was Vice-President of pre-clinical and clinical research at SUGEN, a Pfizer company, and before that held a range of positions of increasing responsibility at Gilead Sciences. Dr Cherrington received her BS in biological sciences and MS in microbiology from the University of California at Davis in 1980 and 1983, respectively. She completed her graduate work in microbiology and immunology at the University of Minnesota and Stanford University in 1990. Dr. Cherrington was a postdoctoral fellow at the University of California at San Francisco from 1990 to 1992 and has co-authored more than 80 peer-reviewed scientific papers. | 